Cardiff Advisory’s David H. Crean outlines how the 2026 JP Morgan Healthcare Conference signaled a shift from sector reset to disciplined re-acceleration in global biopharma. Dr Crean explores investor sentiment,…
Writing in the January 2026 edition of DIA Global Forum, Mariana Socal and Antonio J. Trujillo from the Johns Hopkins Bloomberg School of Public Health and Rachel Goode of Fresenius…
Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
Korea, already one of the world’s top clinical research destinations, is looking to boost the efficiency of its clinical trial processes even further by launching K-CThub, a one-stop digital platform…
Pharma in 2026 will be defined by unpredictability. Executives are already being pushed by shifting policy, commercial, and scientific forces into making fast and tough strategic choices, with more to…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered…
2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX…
Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward…
See our Cookie Privacy Policy Here
